Phase II study of S-1 alternate-day and bevacizumab in elderly patients with advanced colorectal cancer
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2625791
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: S-1 80 mg/m2/day (administration on Mon, Wed, Fri, and Sun) Bevacizumab 7.5 mg/kg (every 3 weeks)
Primary outcome(s): Progression-free survival
Study Design: Single arm Non-randomized
创建时间：
2013-04-15
